| Business Summary | | Genzyme
General
Division
is
a
division
of
Genzyme
Corp.,
a
biotechnology
and
human
healthcare
company
that
develops
products
and
provides
services
for
major
unmet
medical
needs.
Genzyme
General
develops
and
markets
therapeutic
and
diagnostic
products
and
services
with
an
emphasis
on
genetic
disorders
and
other
chronic
debilitating
diseases
with
well-defined
patient
populations.
Genzyme
General
primarily
consists
of
the
Therapeutics
and
Diagnostics
business
units
and
its
wholly
owned
subsidiary
GelTex
Pharmaceuticals,
Inc.,
which
the
Company
acquired
in
December
2000. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GENZ
develops
and
markets
therapeutic
products
and
diagnostic
products
and
services,
with
an
emphasis
on
therapies
for
genetic
diseases.
For
the
six
months
ended
6/01,
revenues
increased
29%
to
$461.7
million.
Net
income
before
acct.
change
fell
42%
to
$71.3
million.
Revenues
reflect
higher
sales
of
Cerezyme(R)
enzyme
replacement
therapy
for
Gaucher
disease
and
sales
growth
of
Renagel(R).
Net
income
was
offset
by
the
absence
of
a
$20.3
million
gain
on
the
sale
of
stock. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Henri Termeer, 55 Chairman,
Pres and CEO | $1.9M | -- | Michael Wyzga, 46 CFO,
Chief Accounting Officer, Sr. VP-Fin. | -- | -- | Earl Collier, Jr., 53 Exec.
VP; Pres, Genzyme Biosurgery | 814K | $1.4M | G. Jan Van Heek, 51 Exec.
VP - Therapeutics and Genetics | 649K | 4.2M | Peter Wirth, 50 CLO;
Exec. VP - Corp. Devel.; Clerk | 772K | 2.5M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|